EUVIMEDEUVIMED entdecken
Crossref

PPARδ Antagonist Inhibited CD47 Expression and Phagocytosis

Yilei Guo, Bibimaryam Khan, Juanjuan Shi, Yongzhong Hou

Journal of Cellular Biochemistry · 2025

DOI: 10.1002/jcb.30685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2025. Verfasst von Yilei Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Wujin Hospital of Jiangsu University (The Wujin Clinical College of Xuzhou Medical University), Changzhou, Jia…. Hauptthemen laut MEDLINE: CD47 Antigen, Phagocytosis, PPAR delta, Colonic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: This work was supported by the National Natural Science Foundation of China (82172979)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increasing evidence suggests that CD47 is highly expressed in multiple types of cancer, which could bind to SIRPα on macrophage, leading to inhibition of macrophage phagocytosis and promotion of tumor growth. However, the regulatory mechanism of CD47 gene expression is not completely clear. Our results indicated that colon cancer cells treated with GSK0660 drug, which is one of the PPARδ antagonists, significantly reduced CD47 gene and protein expression levels in a time and dose‐dependent manner. CD47 reporter plasmid was constructed and dual‐luciferase analysis was performed. The results suggest that GSK0660 treatment markedly reduced CD47 gene transcriptional activity. Moreover, co‐cultured analysis showed that GSK0660 treatment increased phagocytosis. BALB/C mice implanted with CT‐26 colon cancer cells were treated with GSK0660, and the results showed that GSK0660 significantly inhibited tumor growth. Moreover, the combination of CD47 monoclonal antibody with GSK0660 drug significantly inhibited tumor growth compared to GSK0660 or CD47 antibody treatment alone. These findings suggest that GSK0660 synergized with CD47 antibody to enhance antitumor immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD47 AntigenPhagocytosisPPAR deltaColonic NeoplasmsGene Expression Regulation, NeoplasticAnimalsMiceMice, Inbred BALB CHumansCell Line, TumorXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CD47GSK0660colon cancerimmunotherapytranscription

Substanzen

CD47 AntigenPPAR deltaCD47 protein, humanCd47 protein, mouse

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Wujin Hospital of Jiangsu University (The Wujin Clinical College of Xuzhou Medical University), Changzhou, Jiangsu, China.
  • School of Life Science, Jiangsu University, Zhenjiang, Jiangsu, China.

Förderung

  • This work was supported by the National Natural Science Foundation of China (82172979).

Zitieren

APA

Guo, Y., Khan, B., Shi, J., & Hou, Y. (2025). PPARδ Antagonist Inhibited CD47 Expression and Phagocytosis. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30685

Vancouver

Guo Y, Khan B, Shi J, Hou Y. PPARδ Antagonist Inhibited CD47 Expression and Phagocytosis. Journal of Cellular Biochemistry. 2025. doi:10.1002/jcb.30685

BibTeX
@article{Guo2025,
  author = {Guo, Yilei and Khan, Bibimaryam and Shi, Juanjuan and Hou, Yongzhong},
  title = {PPARδ Antagonist Inhibited CD47 Expression and Phagocytosis},
  journal = {Journal of Cellular Biochemistry},
  year = {2025},
  doi = {10.1002/jcb.30685}
}
Kostenlos starten →